20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) agreed to acquire the U.S. rights to Eisai Co Ltd's (OTC:ESALY) (OTC:ESALF) Fycompa (perampanel) CIII and an exclusive option period to review, evaluate and negotiate to acquire a rare epilepsy asset currently in Eisai's pipeline.
- Eisai will receive an upfront payment of $160 million.
- The acquisition adds a highly complementary and established marketed product in neurology that diversifies Catalyst's commercial product portfolio and paves the way for further expansion into other rare neurological diseases.
- U.S. Fycompa net revenues for the fiscal year ending March 31, 2023, will be approximately $136 million.
- Catalyst expects the acquisition to be accretive upon closing to its earnings in 2023 before interest, taxes, depreciation & amortization (EBITDA), and EPS.
- The acquisition is expected to provide Catalyst with a broader commercial product portfolio with the first and only non-competitive AMPA receptor antagonist approved for epilepsy.
- A growing revenue base and a synergistic asset further add to the company's already strong revenue growth of Firdapse.
- Fycompa is expected to have patent protection through at least May 23, 2025, with possible patent protection into 2026.
- Fycompa is indicated for epilepsy in patients aged four and older alone. The deal is expected to close in Q1 of 2023.
- Price Action: CPRX shares closed 3.47% higher at $16.99 during after-hours trading on Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!